Article
Radiology, Nuclear Medicine & Medical Imaging
Iztok Caglic, Nikita Sushentsev, Vincent J. Gnanapragasam, Evis Sala, Nadeem Shaida, Brendan C. Koo, Vasily Kozlov, Anne Y. Warren, Christof Kastner, Tristan Barrett
Summary: The study evaluated the predictive value of the PRECISE scoring system in prostate cancer patients on active surveillance, showing good overall performance with high sensitivity, specificity, and negative predictive value. Prostate-specific antigen density, Likert lesion score, and index lesion size were significant baseline predictors of disease progression.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Lauren Brady, Lisa F. Newcomb, Kehao Zhu, Yingye Zheng, Hilary Boyer, Navonil De Sarkar, Jesse K. McKenney, James D. Brooks, Peter R. Carroll, Atreya Dash, William J. Ellis, Christopher P. Filson, Martin E. Gleave, Michael A. Liss, Frances Martin, Todd M. Morgan, Ian M. Thompson, Andrew A. Wagner, Colin C. Pritchard, Daniel W. Lin, Peter S. Nelson
Summary: The prevalence of pathogenic germline mutations in men with low-risk prostate cancer undergoing active surveillance is extremely low, and these mutations do not appear to be associated with grade reclassification or adverse characteristics.
Article
Oncology
Cristina Marenghi, Zhuyu Qiu, Jozien Helleman, Daan Nieboer, Jose Rubio-Briones, Peter R. Carroll, Lui Shiong Lee, Riccardo Valdagni, Paul C. Boutros, Nicola Nicolai
Summary: Active surveillance is a safe option for low-risk prostate cancer patients, and most patients do not show adverse pathological findings at surgery. However, wider entry criteria are associated with higher tumor extension and positive surgical margins.
Article
Medicine, General & Internal
Lin Li, Rakesh Shiradkar, Patrick Leo, Ahmad Algohary, Pingfu Fu, Sree Harsha Tirumani, Amr Mahran, Christina Buzzy, Verena C. Obmann, Bahar Mansoori, Ayah El-Fahmawi, Mohammed Shahait, Ashutosh Tewari, Cristina Magi-Galluzzi, David Lee, Priti Lal, Lee Ponsky, Eric Klein, Andrei S. Purysko, Anant Madabhushi
Summary: This study developed and validated an integrated radiomic-clinicopathologic nomogram (RadClip) for predicting biochemical recurrence free survival (bRFS) and adverse pathology (AP) in prostate cancer patients. RadClip showed better predictive performance for bRFS and AP compared to Decipher and CAPRA.
Article
Urology & Nephrology
Jordan Nasri, Flora Barthe, Sneha Parekh, Parita Ratnani, Adriana M. Pedraza, Vinayak G. Wagaskar, Jonathan Olivier, Arnauld Villers, Ash Tewari
Summary: This study developed and validated a prediction model to assess the risk of adverse pathology outcome in low-risk prostate cancer patients. The model showed good accuracy in predicting adverse pathology outcomes and could aid in treatment decision-making for this patient population.
Article
Medicine, General & Internal
Alexander Light, Artitaya Lophatananon, Alexandra Keates, Vineetha Thankappannair, Tristan Barrett, Jose Dominguez-Escrig, Jose Rubio-Briones, Toufik Benheddi, Jonathan Olivier, Arnauld Villers, Kirthana Babureddy, Haitham Abdelmoteleb, Vincent J. Gnanapragasam
Summary: Our study aimed to develop and validate a model for predicting the risk of progression on active surveillance (AS) in men with newly diagnosed prostate cancer. The model, which incorporated variables such as PSA, Grade Group, MRI score, and prostate volume, showed good accuracy and clinical utility in both internal and external validation. The model can aid in personalizing AS strategies and offering less-intense surveillance to men with lower risk predictions. Further external validation in larger cohorts is needed to confirm the findings.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Yoichiro Tohi, Ryou Ishikawa, Takuma Kato, Jimpei Miyakawa, Ryuji Matsumoto, Keiichiro Mori, Koji Mitsuzuka, Junichi Inokuchi, Masafumi Matsumura, Kenichiro Shiga, Hirohito Naito, Yasuo Kohjimoto, Norihiko Kawamura, Masaharu Inoue, Shusuke Akamatsu, Naoki Terada, Yoshiyuki Miyazawa, Shintaro Narita, Reiji Haba, Mikio Sugimoto
Summary: It is unclear what factors predict adverse pathology, such as intraductal carcinoma of the prostate and cribriform patterns, in men undergoing active surveillance for prostate cancer. In this study, we found that increasing age could be a predictive factor for adverse pathology. Older individuals may benefit from adhering to an active surveillance schedule.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Hwanik Kim, Gyoohwan Jung, Jin Hyuck Kim, Seok-Soo Byun, Sung Kyu Hong
Summary: PHI can predict GS upgrading in ISUP GG 1 & 2, in conjunction with PIRADS lesions >= 4. PHI alone can also evaluate the likelihood of high-risk PCa after surgery.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Salonee Shah, Kerri Beckmann, Mieke Van Hemelrijck, Ben Challacombe, Rick Popert, Prokar Dasgupta, Jonah Rusere, Grace Zisengwe, Oussama Elhage, Aida Santaolalla
Summary: This study provides a descriptive profile of the Guy's and St Thomas NHS Foundation Trust AS cohort, highlighting the importance of AS pathways. The study found a relatively large proportion of men of African/Afro-Caribbean descent in the cohort, as well as more frequent use of magnetic resonance imaging and trans-perineal biopsies after 2012.
Article
Oncology
Randy A. Vince, Ralph Jiang, Ji Qi, Jeffrey J. Tosoian, Rebecca Takele, Felix Y. Feng, Susan Linsell, Anna Johnson, Sughand Shetty, Patrick Hurley, David C. Miller, Arvin George, Khurshid Ghani, Fionna Sun, Mariana Seymore, Robert T. Dess, William C. Jackson, Matthew Schipper, Daniel E. Spratt, Todd M. Morgan
Summary: The study found that a high-risk Decipher Biopsy score was strongly and independently associated with the conversion from active surveillance to definitive treatment and treatment failure in localized prostate cancer patients. Limitations included follow-up time. These real-world data support the clinical utility of Decipher Biopsy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Oncology
Yasuhide Miyoshi, Takashi Kawahara, Hiroji Uemura
Summary: The study finds that higher serum DHEA concentrations in men with low PSA levels may predict candidates with benign prostatic hyperplasia or low-grade prostate cancer.
Article
Oncology
Wei-jie Gu, Zheng Liu, Yun-jie Yang, Xuan-zhi Zhang, Liang-yu Chen, Fang-ning Wan, Xiao-hang Liu, Zhang-zhe Chen, Yun-yi Kong, Bo Dai
Summary: This study aimed to predict adverse pathology events and biochemical recurrence-free survival based on pre-treatment MRI imaging using the powerful deep learning network NAFNet. The DL-nomogram, including the NAFNet-classifier, clinical T stage, and biopsy results, showed higher accuracy in predicting adverse pathology and biochemical recurrence-free survival compared to other scores. This research highlights the potential application of AI tools in medical imaging risk stratification.
NPJ PRECISION ONCOLOGY
(2023)
Article
Urology & Nephrology
Madhur Nayan, Filipe L. F. Carvalho, Adam S. Feldman
Summary: While active surveillance (AS) is established for low-risk prostate cancer, its safety for intermediate-risk (IR) disease remains uncertain. Lack of randomized trials and limitations of observational studies call for further research to identify which IR prostate cancer patients can be safely managed with AS.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Pathology
Jeffrey Ordner, Abdallah Flaifel, Antonio Serrano, Rebecca Graziano, Jonathan Melamed, Fang-Ming Deng
Summary: The study aimed to determine the prognostic significance of the maximum allowable percentage of Gleason pattern 4 (GP4) at prostate biopsy compared with adverse pathology observed at radical prostatectomy (RP) to expand active surveillance eligibility among a cohort with intermediate risk of prostate cancer. The study found no statistically significant difference in adverse pathology at RP between the active surveillance-eligible control (GP4 0%) and the GP4 <= 5% subgroup, with 68.9% of the GP4 <= 5% subgroup showing favorable pathologic outcomes. Moreover, there was no statistical correlation between prebiopsy serum PSA levels or GP4 length and adverse pathology at RP in the GP4 <= 5% subgroup. Therefore, active surveillance may be a reasonable option for management of patients in the GP4 <= 5% group until long-term follow-up data become available.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Urology & Nephrology
Stefano Luzzago, Mattia Luca Piccinelli, Giulia Marvaso, Ekaterina Laukhtina, Noriyoshi Miura, Victor M. Schuettfort, Keiichiro Mori, Abdulmajeed Aydh, Matteo Ferro, Francesco A. Mistretta, Nicola Fusco, Giuseppe Petralia, Barbara A. Jereczek-Fossa, Shahrokh F. Shariat, Pierre Karakiewicz, Ottavio de Cobelli, Gennaro Musi
Summary: Compared to patients diagnosed with tumors at prostate biopsies (BxPCa), those with incidental prostate cancers (IPCa) are less likely to discontinue Active Surveillance (AS) for any cause or due to biopsy/MRI findings. However, both groups show similar rates of biopsy discontinuation and ISUP GG upgrading over time. Tailored AS protocols with scheduled repeated surveillance biopsies should be offered to all newly diagnosed IPCa patients.
WORLD JOURNAL OF UROLOGY
(2022)
Review
Medical Laboratory Technology
Jonathan Epstein, Mahul B. Amin, Samson W. Fine, Ferran Algaba, Manju Aron, Dilek E. Baydar, Antonio Lopez Beltran, Fadi Brimo, John C. Cheville, Maurizio Colecchia, Eva Comperat, Isabela Werneck da Cunha, Warick Delprado, Angelo M. DeMarzo, Giovanna A. Giannico, Jennifer B. Gordetsky, Charles C. Guo, Donna E. Hansel, Michelle S. Hirsch, Jiaoti Huang, Peter A. Humphrey, Rafael E. Jimenez, Francesca Khani, Qingnuan Kong, Oleksandr N. Kryvenko, L. Priya Kunju, Priti Lal, Mathieu Latour, Tamara Lotan, Fiona Maclean, Cristina Magi-Galluzzi, Rohit Mehra, Santosh Menon, Hiroshi Miyamoto, Rodolfo Montironi, George J. Netto, Jane K. Nguyen, Adeboye O. Osunkoya, Anil Parwani, Brian D. Robinson, Mark A. Rubin, Rajal B. Shah, Jeffrey S. So, Hiroyuki Takahashi, Fabio Tavora, Maria S. Tretiakova, Lawrence True, Sara E. Wobker, Ximing J. Yang, Ming Zhou, Debra L. Zynger, Kiril Trpkov
Summary: Controversies and uncertainty persist in prostate cancer grading. Recommendations include reporting percentage Gleason pattern 4 (%GP4) in needle biopsies, updating tertiary grade patterns, and providing global scores in MRI-targeted biopsies.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2021)
Article
Cell Biology
Harsimar B. Kaur, Daniela C. Salles, Adina Paulk, Jonathan Epstein, James R. Eshleman, Tamara L. Lotan
Summary: PIN-like ductal carcinoma is a rare prostate tumor enriched for potentially targetable oncogenic driver mutations in the RAS/RAF/MAPK pathway. In contrast, conventional ductal adenocarcinoma typically harbors pathogenic mutations in the mismatch repair and homologous recombination DNA repair pathways.
Article
Oncology
Paige K. Kuhlmann, Michelle Chen, Michael Luu, Aurash Naser-Tavakolian, Devin N. Patel, Hyung L. Kim, Rola Saouaf, Timothy J. Daskivich
Summary: Black race and PSA density were associated with presence of MRI-invisible prostate cancer. Systematic biopsy detection of MRI-invisible tumors upgraded patients from no disease to GG2+ disease and from GG1 to GG2+ disease at different rates for non-Black and Black men.
PROSTATE CANCER AND PROSTATIC DISEASES
(2021)
Article
Urology & Nephrology
Eric M. Lo, Hyung L. Kim
UROLOGIC CLINICS OF NORTH AMERICA
(2021)
Article
Urology & Nephrology
Sij Hemal, Molly DeWitt-Foy, Eric A. Klein
Summary: The BRCA gene increases the risk of prostate cancer in men, particularly BRCA2 which leads to a more aggressive form of the disease. The most appropriate screening and management strategy for prostate cancer patients with BRCA mutations is currently unknown.
Article
Oncology
Lamont J. Wilkins, Jeffrey J. Tosoian, Chad A. Reichard, Debasish Sundi, Weranja Ranasinghe, Ridwan Alam, Zeyad Schwen, Chandana Reddy, Mohammed Allaf, John W. Davis, Brian F. Chapin, Ashley E. Ross, Eric A. Klein, Yaw A. Nyame
Summary: Black and White men with high-grade prostate cancer at diagnosis showed similar oncologic outcomes when managed by primary radical prostatectomy. Our findings suggest that racial disparities in prostate cancer mortality are not related to differences in the efficacy of extirpative therapy.
Article
Oncology
Timothy D. Smile, Martin C. Tom, Ahmed Halima, Jay P. Ciezki, Chandana A. Reddy, Kevin L. Stephans, Omar Y. Mian, Ryan X. Zhang, Eric A. Klein, Steven Campbell, James Ulchaker, Kenneth K. Angermeier, Rahul D. Tendulkar
Summary: The addition of androgen deprivation therapy (ADT) to I-125 interstitial brachytherapy did not improve outcomes for patients with unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer. Prospective studies are needed to elucidate the role of ADT in these patients.
Article
Oncology
Chad A. Reichard, Bryan D. Naelitz, Zeneng Wang, Xun Jia, Jianbo Li, Meir J. Stampfer, Eric A. Klein, Stanley L. Hazen, Nima Sharifi
Summary: The baseline serum levels of certain metabolites are associated with an increased risk of lethal prostate cancer. These metabolites are produced through the metabolism mediated by both the human body and gut microbiota. The composition of diet, circulating metabolite levels, and downstream signaling pathways may be modifiable risk factors associated with lethal prostate cancer.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Yanping Wang, Sungyong You, Shengchen Su, Austin Yeon, Eric M. Lo, Sungjin Kim, James L. Mohler, Michael R. Freeman, Hyung L. Kim
Summary: Lowering serum cholesterol enhances antitumor immune response in prostate cancer patients by improving CD8(+) T-cell memory.
CLINICAL CANCER RESEARCH
(2022)
Letter
Medical Laboratory Technology
Eric A. Klein, Tomasz M. Beer, Michael Seiden
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2022)
Article
Pathology
Emily Chan, Jesse K. McKenney, Sarah Hawley, Dillon Corrigan, Heidi Auman, Lisa F. Newcomb, Hilary D. Boyer, Peter R. Carroll, Matthew R. Cooperberg, Eric Klein, Ladan Fazli, Martin E. Gleave, Antonio Hurtado-Coll, Jeffry P. Simko, Peter S. Nelson, Ian M. Thompson, Maria S. Tretiakova, Dean Troyer, Lawrence D. True, Funda Vakar-Lopez, Daniel W. Lin, James D. Brooks, Ziding Feng, Jane K. Nguyen
Summary: The study aimed to determine a quantitative cut-off for distinguishing large and small cribriform glands in prostate cancer. The findings suggest that a size greater than 0.25 mm is associated with more aggressive disease and the potential for metastatic disease, independent of Gleason pattern 5 adenocarcinoma.
Article
Oncology
Liang Qin, Yoon-Mi Chung, Michael Berk, Bryan Naelitz, Ziqi Zhu, Eric Klein, Abhishek A. Chakraborty, Nima Sharifi
Summary: This study reveals that hypoxia followed by reoxygenation in prostate cancer increases the rate-limiting enzyme and cofactors for androgen synthesis, leading to resistance to androgen deprivation therapy. The study also identifies HIF2α as a potential therapeutic target for prostate cancer.
Article
Oncology
Eric A. Klein, Alan Partin, Yair Lotan, Jack Baniel, Martin Dineen, Jason Hafron, Kannan Manickam, Marc Pliskin, Matthew Wagner, Aimee Kestranek, Mark Stovsky
Summary: This study validates the diagnostic performance and predictive value of IsoPSA for High-Grade CaP and Any CaP in men age >= 50 with total PSA >= 4 ng/ml undergoing diagnostic biopsy. IsoPSA outperforms total and % free PSA in discriminating the risk of prostate cancer on biopsy and has the potential to reduce unnecessary biopsies.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Letter
Medicine, General & Internal
Eric A. Klein, Tomasz M. Beer, Michael Seiden
AMERICAN JOURNAL OF MEDICINE
(2023)
Biographical-Item
Oncology
Eric A. Klein
JOURNAL OF CLINICAL ONCOLOGY
(2023)